DOCSLIB.ORG

Utilizing Immunopet to Measure Tumor Response to Treatment in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Utilizing Immunopet to Measure Tumor Response to Treatment in Breast Cancer Wayne State University Wayne State University Dissertations January 2019 Utilizing Immunopet To Measure Tumor Response To Treatment In Breast Cancer Brooke Mcknight Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Bioimaging and Biomedical Optics Commons, and the Biology Commons Recommended Citation Mcknight, Brooke, "Utilizing Immunopet To Measure Tumor Response To Treatment In Breast Cancer" (2019). Wayne State University Dissertations. 2176. https://digitalcommons.wayne.edu/oa_dissertations/2176 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. UTILIZING IMMUNOPET TO MEASURE TUMOR RESPONSE TO TREATMENT IN BREAST CANCER by BROOKE N. MCKNIGHT DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2018 MAJOR: CANCER BIOLOGY Approved By: Advisor Date DEDICATION I dedicate this to all of the little girls who dream of seeing, learning, and becoming “more”, and to the people who support them every step of the way. To those of you who did that for me - thank you for giving me “more”. i ACKNOWLEDGEMENTS Throughout my graduate career, I have received the support and guidance from many people who deserve my appreciation. This work would not have been possible without the support of my advisor, committee, colleagues, family, and friends. Advisor I would like to express my sincere gratitude to Dr. Nerissa Viola, who has been my advisor throughout my dissertation work. Thank you for providing me with an environment to learn, design projects, and cultivate the skills necessary to have a successful career. Without Dr. Viola, this project would not have been possible, and I am grateful for her wealth of knowledge and generosity that made it happen. Committee Throughout my dissertation research, I have received advice and encouragement from each of the members on my committee. Each mentor has provided me with valuable insight and expertise that has taken my project to another level. Dr. Anthony Shields has provided a clinical perspective to my project and has been an invaluable source of knowledge regarding imaging aspects of the experiments. Dr. Wei-Zen Wei has provided immunology expertise, without which the fourth chapter of this dissertation would cease to exist. She has also served as a co-mentor during my F-31 grant submission. Dr. Julie Boerner has been an advocate of mine since I was recruited into the program under her direction and has since provided vital insight into the biology of Src and the HER family signaling pathway. Dr. Matt Allen has challenged me with thoughtful questions regarding the chemistry of my projects, which has allowed me to gain this experience*. Each of my ii committee members has provided me with mentorship for which I am especially grateful. Viola Lab Each member of the Viola lab has been a great source of support and friendship during my entire time in the lab. Jordan White has been a wonderful friend and peer. I am thankful for his help in keeping the lab organized and performing/troubleshooting experiments side-by-side on the days when I needed a little extra push to get going. I also am grateful for our similar taste in music, and the ability to rock out to 90s pop hits, 2000s hip hop, and Christmas music year-round. Dr. Akhila Kuda-Wedagedara has been a surrogate “big brother” in the lab, sharing with me his insights into the PhD process, helping me with the chemistry of my experiments, and acting as a sounding board when designing experiments. Colleagues I would also like to thank Dr. Heather Gibson, Claire McCarthy, and Joyce Reyes for their hands-on involvement in the project described in chapter 4. Agnes Malaysa, Dr. Lisa Polin, Kirk Douglas, Dr. Jessica Back, Xin Liu, Dr. Tom Mangner, Karri Stark, and the DLAR staff have all provided me with the support, knowledge, and hands-on assistance with various parts of my experiments, and I would have been much less organized without your attention to detail and expertise. Thank you all. Cancer Biology Graduate Program Of course, I must also thank the Cancer Biology Graduate Program for their continued support and guidance through this entire process. I would like to thank Dr. Larry Matherly for his management of the CB program and his interest in the success of the students. To Dr. George Brush, thank you for all of your input and advice over the years, iii and for always making sure I have submitted my IDP correctly and on time. And to Nadia Daniel, thank you for always making sure the “trains run on time” – without your continued enthusiasm and dedication for the program and my personal success I would not be where I am today. Additionally, I would like to extend my sincere gratitude to the steering committee members from 2014-2018 for fostering a research-focused environment for the students to flourish. Additional Significant Support I must now thank the students, whom without there would be no program. I would like to specifically thank a few of the graduates who have provided me with invaluable insight, support, encouragement, and stories – Drs. Stephanie Blocker, Tom McFall, Rayna Rosatti, Chris McHugh, and Dan Feldmann. And to a few of the current students who are my confidants, friends, and consultants – Josh Heyza, Anthony Guastella, Laura Hurley, Nico Moses, Ethan Brock, Allison Mitchell, Kayla Connor, Adrianne Wallace- Povirk, and Josh Mandella – thank you for always being a text message, lab-themed snapchat, or Starbucks break away. I would additionally like to thank Dr. David Ginsburg, Dr. Rami Khoriaty, Dr. Leslie Everett, and Suzann Labun for taking a chance on me back in 2013 when I was a junior at the University of Michigan. Without your support and training, countless letters of recommendation, abstract and CV editing, and continued advice, I would not be where I am today. Family I would like to acknowledge the people whose battles inspired me to apply for this PhD in particular. First, to my grandma-angel, Marilyn Gravila, who lost her 30-year battle iv in 2000. Next, to my dad, and my cousins Brad Foster and Derek Adams, who have won or are still fighting their battles. Finally, to the countless family-friends who have allowed me to probe into their experiences for the purpose of expanding my cancer knowledge – your kindness in sharing your stories has made me a better scientist. I would like to extend the largest thank you to my immediate family. None of my accomplishments would have been possible if not for your constant support, encouragement, and love. I want to give the most heartfelt thanks to everything they have done to keep me motivated throughout this process. To my dad, Mark McKnight, thank you for always being my confidence – even when I am not sure of myself. You have always pushed me to be better and do more, and I am forever grateful. I would like to thank my mom, Michelle McKnight, who has taught me everything I know about being a strong and intelligent woman. You have always been my rock and sounding board, and I thank you for your constant support. Together, you have provided me with a solid foundation to build a life upon, and I couldn’t have done any of this without your financial support. Thank you from the bottom of my heart for the sacrifices you both made to provide me with a wonderful life. I would like to thank my “bonus family” – John, Cheryl, Jared, and Jordan Dickow. You have all been here with me since sophomore year in college, so I feel as if you’ve been a part of this process every step of the way. Thank you for all of the phone calls, advice, and your constant curiosity in what I am doing, even if after a few minutes of explanation you wish you hadn’t asked after all. I will forever cherish the holidays, weekends, and game nights spent together, that provided me with a little “escape” from v my constant studying. Last but not least, I thank my husband, Justin Dickow. Who would’ve thought that back in 2011 when we met and began our relationship by spending countless hours studying at the BBB building and the Dude at the University of Michigan that we were setting up our lives for the next decade. Without your continued support, coaching, and “tough love” (when it comes to academics and my study habits), I would have never learned how to push myself academically or been able to complete a PhD. I owe this all to you and am so glad we can share in the fun times now that school is over! (for now…) vi TABLE OF CONTENTS DEDICATION ................................................................................................................... i ACKNOWLEDGEMENTS ................................................................................................ii TABLE OF CONTENTS ................................................................................................. vii LIST OF TABLES ........................................................................................................... xii LIST OF FIGURES ........................................................................................................ xiv LIST OF ABBREVIATIONS .......................................................................................... xvii CHAPTER 1: INTRODUCTION ......................................................................................
Load more

Recommended publications
  • Strategies to Enhance Monoclonal Antibody Uptake and Distribution in Solid Tumors
    Cancer Biol Med 2021. doi: 10.20892/j.issn.2095-3941.2020.0704 REVIEW Strategies to enhance monoclonal antibody uptake and distribution in solid tumors Brandon M. Bordeau, Joseph P. Balthasar Department of Pharmaceutical Science, University at Buffalo, Buffalo, NY 14214, USA ABSTRACT Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor physiology. Solid tumors have an aberrant vasculature and a dense extracellular matrix that slow both the convective and diffusive transport of mAbs into and within tumors. For mAbs that are directed against cellular antigens, high antigen expression and rapid antigen turnover can result in perivascular cells binding to and eliminating a significant amount of extravasated mAb, limiting mAb distribution to portions of the tumor that are distant from functional vessels. Many preclinical investigations have reported strategies to improve mAb uptake and distribution; however, to our knowledge, none have translated into the clinic. Here, we provide an overview of several barriers in solid tumors that limit mAb uptake and distribution and discuss approaches that have been utilized to overcome these barriers in preclinical studies. KEYWORDS Solid tumors; antibody uptake and distribution; monoclonal antibody; antibody–drug conjugate Introduction Currently, monoclonal antibodies (mAbs) are heralded as the “magic bullets” that Ehrlich envisioned, and in many cases, the In 1900, Paul Ehrlich developed the receptor theory, which moniker is well deserved. Antibodies can bind most substances was built on the foundational hypothesis that toxins, nutri- with high affinity and high selectivity and are used for the treat- ents, and drugs exert their observed effect through binding to ment of many diseases.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology
    Figure 1. This is a pilot view to explore the potential of EpiGraphDB to inform us about proteins that are linked to the pathophysiology of cancer and cardiovascular disease (CVD). For each cancer type (pink diamonds), we searched for cancer related proteins (light blue circles) that interact with other proteins identified as protein quantitative trait loci (pQTLs) for CVD (red diamonds for pathologies, orange triangles for risk factors). These pQTLs can be acting in cis (solid lines) or trans-acting (dotted lines). Proteins can interact either directly, a protein-protein interaction (dotted blue edges), or through the participation in the same pathway (red parallel lines). Shared pathways are represented with blue hexagons. We also queried which of these proteins are targeted by existing drugs. We found that the cancer drug cetuximab (yellow circle) inhibits EGFR. Other potential drugs are depicted in light brown hexagonal meta-nodes that are detailed below. Deciphering molecular mechanisms and prioritizing therapeutic targets in cardio-oncology Pau Erola1,2, Benjamin Elsworth1,2, Yi Liu2, Valeriia Haberland2 and Tom R Gaunt1,2,3 1 CRUK Integrative Cancer Epidemiology Programme; 2 MRC Integrative Epidemiology Unit, University of Bristol; 3 The Alan Turing Institute Cancer and cardiovascular disease (CVD) make by far the immense What is EpiGraphDB? contribution to the totality of human disease burden, and although mortality EpiGraphDB is an analytical platform and graph database that aims to is declining the number of those living with the disease shows little address the necessity of innovative and scalable approaches to harness evidence of change (Bhatnagar et al., Heart, 2016).
    [Show full text]
  • Version Introducing VHIO Foreword
    2017SCIENTIFIC REPORT Vall d'Hebron Institute of Oncology (VHIO) CELLEX CENTER C/Natzaret, 115 – 117 08035 Barcelona, Spain Tel. +34 93 254 34 50 www.vhio.net Direction: Amanda Wren Design: Parra estudio Photography: Katherin Wermke Vall d'Hebron Institute of Oncology (VHIO) | 2018 VHIO Scientific Report 2017 Index Scientific Report INTRODUCING VHIO CORE TECHNOLOGIES 02 Foreword 92 Cancer Genomics Group 08 2017: marking the next chapter of 94 Molecular Oncology Group VHIO's translational story 96 Proteomics Group 18 Scientific Productivity: research articles VHIO'S TRANSVERSAL CLINICAL 19 Selection of some of the most relevant TRIALS CORE SERVICES & UNITS articles by VHIO researchers published in 2017 100 Clinical Trials Office 25 A Golden Decade: reflecting on the 102 Research Unit for Molecular Therapy past 10 years of VHIO's translational of Cancer (UITM) – ”la Caixa” success story 104 Clinical Research Oncology Nurses 106 Clinical Research Oncology Pharmacy PRECLINICAL RESEARCH Unit 49 From the Director 50 Experimental Therapeutics Group RECENTLY INCORPORATED GROUPS 52 Growth Factors Group 110 Cellular Plasticity & Cancer Group 54 Mouse Models of Cancer Therapies 112 Experimental Hematology Group Group 114 Tumor Immunology 56 Tumor Biomarkers Group & Immunotherapy Group 116 Applied Genetics of Metastatic Cancer TRANSLATIONAL RESEARCH Group 61 From the Director 118 Chromatin Dynamics in Cancer Group 62 Gene Expression & Cancer Group 120 Prostate Cancer Translational Research Group 64 Stem Cells & Cancer Group 122 Radiomics Group CLINICAL
    [Show full text]
  • Roche/Genentech Managed RG7986 ADC R/R NHL CHU Chugai Managed IONIS IONIS Managed 74 Status As of January 28, 2016 PRO Proximagen Managed
    Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab
    Author Manuscript Published OnlineFirst on March 5, 2018; DOI: 10.1158/1078-0432.CCR-17-0646 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Page 1 of 27 Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) versus cetuximab in combination with FOLFIRI in second line RAS wild-type metastatic colorectal cancer Andrew G. Hill,1 Michael P. Findlay,2 Matthew E. Burge,3 Christopher Jackson,4 Pilar Garcia Alfonso,5 Leslie Samuel,6 Vinod Ganju,7 Meinolf Karthaus,8 Alessio Amatu,9 Mark Jeffery,10 Maria Di Bartolomeo,11 John Bridgewater,12 Andrew L. Coveler,13 Manuel Hidalgo,14 Amy V. Kapp,15 Roxana I. Sufan,15 Bruce B. McCall,15 William D. Hanley,15 Elicia M. Penuel,15 Andrea Pirzkall,15 Josep Tabernero16 1Tasman Oncology Research, Southport, Australia 2Discipline of Oncology, University of Auckland, Auckland, New Zealand 3Royal Brisbane and Women's Hospital, Herston, Australia; University of Queensland, Queensland, Australia 4Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand 5Gregorio Marañón Hospital, Madrid, Spain 6Aberdeen Royal Infirmary, Aberdeen, UK 7Peninsula Oncology Centre, Frankston, Australia 8Staedtisches Klinikum Muenchen GmbH - Klinikum Neuperlach, Munich, Germany 9Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy 10Canterbury Regional Cancer and Haematology Service, Christchurch, New Zealand 11Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 12University College London Cancer Institute, London, UK 13University of Washington, Seattle, WA, USA 14Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain 15Genentech, Inc., South San Francisco, CA, USA 16Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain Corresponding author: Andrew G.
    [Show full text]
  • Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Į S a K Y M a S
    VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO Į S A K Y M A S DĖL VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO 2006 M. LAPKRIČIO 2 D. ĮSAKYMO NR. 1A-658 „DĖL TARPTAUTINIŲ PREKĖS ŽENKLU NEREGISTRUOTŲ VAISTINIŲ MEDŽIAGŲ PAVADINIMŲ ATITIKMENŲ LIETUVIŲ KALBA SĄRAŠO PATVIRTINIMO“ PAKEITIMO 2013 m. gegužės 2 d. Nr. (1.4)1A-480 Vilnius Atsižvelgdamas į Pasaulio sveikatos organizacijos 2013 m. paskelbtą 69-ąjį Rekomenduojamų tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų (INN) sąrašą, p a k e i č i u Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašą, patvirtintą Valstybinės vaistų kontrolės tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos viršininko 2006 m. lapkričio 2 d. įsakymu Nr. 1A-658 „Dėl Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašo patvirtinimo“ (Žin., 2006, Nr. 119-4557; 2007, Nr. 13-519; 2008, Nr. 24-896; 2010, Nr. 152-7773; 2011, Nr. 56-2700, Nr. 159-7553; 2012, Nr. 53-2664, Nr. 113-5776): 1. Papildau nauja eilute, kurią po eilutės „Actodigin Aktodiginas Actodiginum“ išdėstau taip: „Actoxumab Aktoksumabas Actoxumabum“ 2. Papildau nauja eilute, kurią po eilutės „Alacizumab pegol Alacizumabas pegolas Alacizumabum pegolum“ išdėstau taip: „Aladorian Aladorianas Aladorianum“ 3. Papildau nauja eilute, kurią po eilutės „Alipogene tiparvovec Alipogenas tiparvovekas Alipogenum tiparvovecum“ išdėstau taip: „Alirocumab Alirokumabas Alirocumabum“ 4. Papildau nauja eilute, kurią po eilutės „Antithrombin alfa Antitrombinas alfa Antithrombinum alfa“ išdėstau taip: „Antithrombin gamma Antitrombinas gama Antithrombinum gamma“ 5. Papildau nauja eilute, kurią po eilutės „Astromicin Astromicinas Astromicinum“ išdėstau taip: „Asudemotide Asudemotidas Asudemotidum“ 6. Papildau nauja eilute, kurią po eilutės „Auranofin Auranofinas Auranofinum“ išdėstau taip: „Auriclosene Auriklozenas Auriclosenum“ 7.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • ADCC Responses and Blocking of EGFR-Mediated Signaling and Cell Growth by Combining the Anti-EGFR Antibodies Imgatuzumab and Cetuximab in NSCLC Cells
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 28), pp: 45432-45446 Research Paper ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells Arjan Kol1, Anton Terwisscha van Scheltinga2, Martin Pool1, Christian Gerdes3, Elisabeth de Vries1 and Steven de Jong1 1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 3Roche Pharma Research & Early Development, Roche Innovation Center Zürich, Schlieren, Switzerland Correspondence to: Steven de Jong, email: [email protected] Keywords: non-small cell lung cancer, EGFR, imgatuzumab, cetuximab, antibodies Received: October 19, 2016 Accepted: March 30, 2017 Published: April 17, 2017 Copyright: Kol et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Imgatuzumab is a novel glycoengineered anti-epidermal growth factor receptor (EGFR) monoclonal antibody optimized to induce both antibody-dependent cellular cytotoxicity (ADCC) and EGFR signal transduction inhibition. We investigated anti- EGFR monoclonal antibodies imgatuzumab and cetuximab–induced internalization and membranous turnover of EGFR, and whether this affected imgatuzumab–mediated ADCC responses and growth inhibition of non-small cell lung cancer (NSCLC) cells. In a panel of wild-type EGFR expressing human NSCLC cell lines, membranous and total EGFR levels were downregulated more effectively by imgatuzumab when compared with cetuximab.
    [Show full text]
  • Targeting Erbb3 Receptor in Cancer with Inhibitory Antibodies from Llama
    biomedicines Article Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama Igor E. Eliseev 1,2,3,* , Valeria M. Ukrainskaya 3, Anna N. Yudenko 4 , Anna D. Mikushina 1, Stanislav V. Shmakov 1, Anastasiya I. Afremova 5, Viktoria M. Ekimova 5, Anna A. Vronskaia 1, Nickolay A. Knyazev 6 and Olga V. Shamova 2 1 Laboratory of Renewable Energy Sources, Alferov University, St. Petersburg 194021, Russia; [email protected] (A.D.M.); [email protected] (S.V.S.); [email protected] (A.A.V.) 2 Center for Personalized Medicine, FSBSI Institute of Experimental Medicine, St. Petersburg 197376, Russia; [email protected] 3 Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia; [email protected] 4 Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia; [email protected] 5 CJSC Biocad, St. Petersburg 198515, Russia; [email protected] (A.I.A.); [email protected] (V.M.E.) 6 Saint-Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), St. Petersburg 197758, Russia; [email protected] * Correspondence: [email protected] Abstract: The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti- Citation: Eliseev, I.E.; Ukrainskaya, ErbB3 monoclonal antibodies that are currently being developed are all classical immunoglobulins. V.M.; Yudenko, A.N.; Mikushina, We took a different approach and discovered a group of novel heavy-chain antibodies targeting the A.D.; Shmakov, S.V.; Afremova, A.I.; extracellular domain of ErbB3 via a phage display of an antibody library from immunized llamas.
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]